---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-22-000110"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2022-11-28T23:59:59+00:00"
generated_at: "2026-06-21T12:46:53.197570+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# LivaNova's RECOVER depression trial enrollment expanded to 425 unipolar patients after interim analysis

## Summary
- Independent Statistical Analysis Committee advised continuing enrollment to 425 unipolar patients, up from 400.
- Interim analyses occur every 25 patients; cessation of RCT enrollment when predictive probability threshold met.
- Final analysis after 12-month follow-up of last RCT patient; data to support CMS reimbursement reconsideration for VNS Therapy.
- Company disclosed the update via Form 8-K on November 28, 2022, regarding event on November 23, 2022.

## SEC filing metadata
- accession: 0001639691-22-000110
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2022-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969122000110/0001639691-22-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969122000110/livn-20221123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-22-000110
- JSON: https://secwatch.observer/filing/0001639691-22-000110.json
- Plain text: https://secwatch.observer/filing/0001639691-22-000110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.